Apotex, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
- Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – GlobalData’s summarization of the company’s business strategy. - SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. - Company history – Progression of key events associated with the company. - Major products and services – A list of major products, services and brands of the company. - Key competitors – A list of key competitors to the company. - Key employees – A list of the key executives of the company. - Executive biographies – A brief summary of the executives’ employment history. - Key operational heads – A list of personnel heading key departments/functions. - Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details. - Key manufacturing facilities – A list of key manufacturing facilities of the company.
Apotex, Inc. (Apotex) is a pharmaceutical company. It carries out the production and marketing of a wide range of generic pharmaceuticals. It also undertakes the research, development, manufacturing and distribution of non-prescription and private label medicines, fine chemicals and disposable plastics for medicinal use. The company focuses on providing an array of affordable medicines to patients, healthcare providers, payers and governments worldwide. The company operates through affiliates in Canada, Mexico, the US, Belgium, Argentina, Czech Republic, Italy, the Netherlands, Poland, Spain, Australia, India, New Zealand, Saudi Arabia and Turkey. It also has manufacturing and distribution facilities worldwide. Apotex is headquartered in Toronto, Ontario, Canada.
Apotex, Inc. Key Recent Developments
Aug 22, 2013: Apotex Inc. invests in patient care reinvented: pledges $10 Million in support of the New Humber River Hospital May 25, 2013: Apotex And Pro Doc Provide Safety Information On Apo-Clindamycin, Clindamycine-150 And Clindamycine-300 Mar 13, 2013: FTC Files Amicus Brief On Improper Use Of Restricted Drug Distribution Programs Feb 21, 2013: Apotex Receives FDA Warning Letter
Reasons to Buy
- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs. - Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy. - Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company. - Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
Table Of Contents
Apotex, Inc. - Strategic SWOT Analysis Review Table of Contents Section 1 - About the Company 6 Apotex, Inc. - Key Facts 6 Apotex, Inc. - Key Employees 7 Apotex, Inc. - Key Employee Biographies 8 Apotex, Inc. - Major Products and Services 9 Apotex, Inc. - History 11 Apotex, Inc. - Company Statement 14 Apotex, Inc. - Locations And Subsidiaries 15 Head Office 15 Other Locations and Subsidiaries 15 Section 2 - Company Analysis 17 Apotex, Inc. - Business Description 17 Apotex, Inc. - SWOT Analysis 18 SWOT Analysis - Overview 18 Apotex, Inc. - Strengths 18 Strength - Dominant Market Position 18 Strength - Strong In-house Research Capabilities 18 Strength - Global Network 18 Apotex, Inc. - Weaknesses 19 Weakness - Product Recalls 19 Weakness - Locked-up Enterprise Value 19 Apotex, Inc. - Opportunities 20 Opportunity - Strategic Initiatives 20 Opportunity - Resuming Shipping to the US 20 Apotex, Inc. - Threats 21 Threat - Stringent Government Regulations 21 Threat - Uncertain RandD Outcomes 21 Threat - Highly Competitive Generic Drug Market 21 Apotex, Inc. - Key Competitors 22 Section 3 - Company's Lifesciences Financial Deals and Alliances 23 Apotex, Inc., Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 23 Apotex, Inc., Pharmaceuticals and Healthcare, Deals By Type, 2009 to YTD 2015 24 Apotex, Inc., Recent Deals Summary 25 Section 4 - Company's Recent Developments 26 Dec 12, 2014: Panacea Biotec Announces Strategic Alliance With Apotex 26 Dec 03, 2014: Meda and Cipla sue Apotex to enforce DymistaÂ® patents 27 Sep 24, 2014: Information Update - Health Canada requests quarantine of products for Canadian market from Apotex facility in Bangalore, India 28 Aug 26, 2014: Apotex Announces Dr. Jeremy B. Desai as President and CEO 29 Aug 26, 2014: Appointment Announcement - Dr. Jeremy B. Desai, President and CEO, Apotex 30 Section 5 - Appendix 31 Methodology 31 About GlobalData 31 Contact Us 31 Disclaimer 31
List of Tables Apotex, Inc., Key Facts 6 Apotex, Inc., Key Employees 7 Apotex, Inc., Key Employee Biographies 8 Apotex, Inc., Major Products and Services 9 Apotex, Inc., History 11 Apotex, Inc., Other Locations 15 Apotex, Inc., Subsidiaries 15 Apotex, Inc., Key Competitors 22 Apotex, Inc., Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 23 Apotex, Inc., Pharmaceuticals and Healthcare, Deals By Type, 2009 to YTD 2015 24 Apotex, Inc., Recent Deals Summary 25
List of Figures Apotex, Inc., Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 23 Apotex, Inc., Pharmaceuticals and Healthcare, Deals by Type, 2009 to YTD 2015 24